Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Kotra Industries Bhd's Revenue for the
three
months ended in Mar. 2026 was RM52.5 Mil. Kotra Industries Bhd's average Accounts Receivable for the
three
months ended in Mar. 2026 was RM38.5 Mil.
Hence, Kotra Industries Bhd's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.36.
Kotra Industries Bhd (XKLS:0002) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Kotra Industries Bhd Receivables Turnover Related Terms
Kotra Industries Bhd Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Kotra Industries Bhd's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0002 vs ZTS, UTHR, VTRS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kotra Industries Bhd's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kotra Industries Bhd Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kotra Industries Bhd's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Kotra Industries Bhd's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kotra Industries Bhd (XKLS:0002) has a Receivables Turnover of 1.36 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Kotra Industries Bhd and its competitors. According to the industry distribution chart, Kotra Industries Bhd ranks #326 out of 950 companies in the Drug Manufacturers industry, placing it in the top 34.3%.
Is Kotra Industries Bhd's Receivables Turnover too high?
Kotra Industries Bhd's current Receivables Turnover is 1.36. The Drug Manufacturers industry median Receivables Turnover is 5.07. Kotra Industries Bhd's value of 1.36 is 73.2% below this industry median. Based on the distribution chart, Kotra Industries Bhd ranks #326 out of 950 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kotra Industries Bhd has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kotra Industries Bhd's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kotra Industries Bhd ranks #326 out of 950 companies for Receivables Turnover. This puts Kotra Industries Bhd in the upper half of its industry. The industry median Receivables Turnover is 5.07. Kotra Industries Bhd's value of 1.36 is 73.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kotra Industries Bhd's current Receivables Turnover of 1.36 is 73.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Kotra Industries Bhd and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kotra Industries Bhd's current Receivables Turnover is 1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kotra Industries Bhd stock overvalued right now?
Based on GuruFocus' analysis, Kotra Industries Bhd (XKLS:0002) is currently considered Modestly Undervalued. The stock's GF Value™ is RM4.34, compared to a current price of RM3.70 — trading 14.7% below its estimated fair value. The current Receivables Turnover is 1.36 and 73.2% below the Drug Manufacturers industry median of 5.07. Kotra Industries Bhd's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Kotra Industries Bhd (XKLS:0002), the current Receivables Turnover is 1.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kotra Industries Bhd (XKLS:0002) Overvalued in 2026?
Based on GuruFocus' analysis, Kotra Industries Bhd stock appears to be undervalued.
The current stock price of RM3.70 is trading 14.7% below its estimated GF Value™ of RM4.34.
GuruFocus considers Kotra Industries Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0002:
Receivables Turnover: 1.36
GF Value™: RM4.34 vs. price of RM3.70 (14.7% below fair value)
Industry Position: 73.2% below the Drug Manufacturers median (#326 of 950)
No single metric tells the full story. See the XKLS:0002 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kotra Industries Bhd is a Malaysian pharmaceutical company engaged in the development, manufacturing, and supply of pharmaceutical and healthcare products supporting all life stages. Its portfolio includes life-saving medicines, OTC supplements, and nutrition products. The Group markets three core brands: Appeton, offering health supplements and nutrition across all age groups; Vaxcel, providing injectable medicines for infectious diseases, kidney care, and gastroenterology; and Axcel, specializing in oral and topical medicines for paediatrics, dermatology, and infectious diseases. The company operates in Malaysia and overseas, with the majority of revenue derived from Malaysia.
83GF Score
Get the complete analysis for XKLS:0002
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0002 has been successfully added to your 
